240 related articles for article (PubMed ID: 22947426)
1. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial.
Winston DJ; Saliba F; Blumberg E; Abouljoud M; Garcia-Diaz JB; Goss JA; Clough L; Avery R; Limaye AP; Ericzon BG; Navasa M; Troisi RI; Chen H; Villano SA; Uknis ME;
Am J Transplant; 2012 Nov; 12(11):3021-30. PubMed ID: 22947426
[TBL] [Abstract][Full Text] [Related]
2. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
Papanicolaou GA; Silveira FP; Langston AA; Pereira MR; Avery RK; Uknis M; Wijatyk A; Wu J; Boeckh M; Marty FM; Villano S
Clin Infect Dis; 2019 Apr; 68(8):1255-1264. PubMed ID: 30329038
[TBL] [Abstract][Full Text] [Related]
3. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.
Winston DJ; Young JA; Pullarkat V; Papanicolaou GA; Vij R; Vance E; Alangaden GJ; Chemaly RF; Petersen F; Chao N; Klein J; Sprague K; Villano SA; Boeckh M
Blood; 2008 Jun; 111(11):5403-10. PubMed ID: 18285548
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
Park JM; Lake KD; Arenas JD; Fontana RJ
Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
[TBL] [Abstract][Full Text] [Related]
5. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.
Marty FM; Ljungman P; Papanicolaou GA; Winston DJ; Chemaly RF; Strasfeld L; Young JA; Rodriguez T; Maertens J; Schmitt M; Einsele H; Ferrant A; Lipton JH; Villano SA; Chen H; Boeckh M;
Lancet Infect Dis; 2011 Apr; 11(4):284-92. PubMed ID: 21414843
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
Razonable RR
World J Gastroenterol; 2008 Aug; 14(31):4849-60. PubMed ID: 18756591
[TBL] [Abstract][Full Text] [Related]
7. Maribavir: a novel antiviral agent with activity against cytomegalovirus.
Trofe J; Pote L; Wade E; Blumberg E; Bloom RD
Ann Pharmacother; 2008 Oct; 42(10):1447-57. PubMed ID: 18698013
[TBL] [Abstract][Full Text] [Related]
8. Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263.
Drugs R D; 2007; 8(3):188-92. PubMed ID: 17472414
[TBL] [Abstract][Full Text] [Related]
9. In vitro studies of the impact of maribavir on CMV-specific cellular immune responses.
Stachel D; Stevens-Ayers T; Boeckh M
J Clin Virol; 2016 Feb; 75():53-9. PubMed ID: 26780109
[TBL] [Abstract][Full Text] [Related]
10. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Noble S; Faulds D
Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
[TBL] [Abstract][Full Text] [Related]
11. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial.
Singh N; Yu VL; Mieles L; Wagener MM; Miner RC; Gayowski T
Ann Intern Med; 1994 Mar; 120(5):375-81. PubMed ID: 8304654
[TBL] [Abstract][Full Text] [Related]
12. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
[TBL] [Abstract][Full Text] [Related]
13. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
[TBL] [Abstract][Full Text] [Related]
14. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
Maertens J; Cordonnier C; Jaksch P; Poiré X; Uknis M; Wu J; Wijatyk A; Saliba F; Witzke O; Villano S
N Engl J Med; 2019 Sep; 381(12):1136-1147. PubMed ID: 31532960
[TBL] [Abstract][Full Text] [Related]
15. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.
Turgeon N; Fishman JA; Doran M; Basgoz N; Tolkoff-Rubin NE; Cosimi AB; Rubin RH
Transpl Infect Dis; 2000 Mar; 2(1):2-10. PubMed ID: 11429003
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.
Paya C; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Pescovitz MD;
Am J Transplant; 2004 Apr; 4(4):611-20. PubMed ID: 15023154
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
Badley AD; Seaberg EC; Porayko MK; Wiesner RH; Keating MR; Wilhelm MP; Walker RC; Patel R; Marshall WF; DeBernardi M; Zetterman R; Steers JL; Paya CV
Transplantation; 1997 Jul; 64(1):66-73. PubMed ID: 9233703
[TBL] [Abstract][Full Text] [Related]
18. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial.
Singh N; Paterson DL; Gayowski T; Wagener MM; Marino IR
Transplantation; 2000 Sep; 70(5):717-22. PubMed ID: 11003347
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
